Gastrointestinal Cancer News

Roswell Park Comprehensive Cancer Center announced the hiring or promotion of several people across clinical, administrative and research departments.

Overall cancer mortality in the U.S. decreased by 31% between 1991 and 2018 amid continued advances in lung cancer treatment, according to American Cancer Society’s 70th annual report on cancer statistics.

The FDA granted fast track designation to zenocutuzumab for treatment of patients with metastatic solid tumors that harbor neuregulin 1 fusion cancers that progressed on standard therapy.

Oral bacteria appeared to be more abundant in patients with esophageal cancer compared with otherwise healthy controls, according to results of a study published in Cancer.

Approximately one in five patients with cancer reported they were less likely to participate in a clinical trial because of concerns about the COVID-19 pandemic, according to a research letter in JAMA Oncology.

The FDA has approved or granted special designations to several oncology or hematology agents over the past 2 weeks.

Pembrolizumab plus fluoropyrimidine-based chemotherapy received FDA priority review for the first-line treatment of locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer, according to a press release.

The rate of early-onset esophageal adenocarcinoma increased an average of 2.9% per year between 1975 and 2015, according to results of a study published in Cancer Epidemiology, Biomarkers & Prevention.

Mark A. Lewis, MD, is a medical oncologist specializing in cancers of the gastrointestinal tract and accessory organs. In this episode, he talks about his path to becoming a GI oncologist and living with multiple endocrine neoplasia type 1.

The increasing prevalence and troubling consequences of obesity in the United States have been well-documented.